Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.43 |
| ▸ | PTGES | O14684 | 3/20 | 0.39 |
| ▸ | CSNK2A2 | P19784 | 8/20 | 0.38 |
| ▸ | CSNK2B | P67870 | 8/20 | 0.38 |
| ▸ | PIM1 | P11309 | 7/20 | 0.38 |
| ▸ | PIM3 | Q86V86 | 7/20 | 0.38 |
| ▸ | PIM2 | Q9P1W9 | 7/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.34 |
| ▸ | SPR | P35270 | 1/20 | 0.34 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.34 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.34 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | FLT1 | P17948 | 1/20 | 0.34 |
| ▸ | FLT4 | P35916 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.34 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2127203 | 0.85 | PRKD3 (0.47) | PTGESCSNK2A2CSNK2BPIM1PIM3 | |
| SCHEMBL2128135 | 0.79 | ADORA1 (0.34) | PTGESCSNK2A2CSNK2BPIM1PIM3 | |
| SCHEMBL14238166 | 0.79 | TNKS2 (0.50) | GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL2127006 | 0.78 | AMY1A (0.43) | AMY1APTGESCSNK2A2CSNK2BPIM1 | |
| SCHEMBL2130092 | 0.71 | MGAM (0.50) | GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL17816407 | 0.71 | TNKS (0.63) | AMY1A | |
| SCHEMBL2125422 | 0.71 | TGFBR1 (0.50) | AMY1APTGESTGFBR1PRKD3PRKD1 | |
| SCHEMBL27732302 | 0.71 | TGFBR1 (0.42) | AMY1ATGFBR1PRKD3PRKD1PRKD2 | |
| SCHEMBL2125639 | 0.69 | GAA (0.50) | PTGES | |
| SCHEMBL29793225 | 0.67 | MC4R (0.48) | AMY1AGABRA1GABRA5GABRA3GABRA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9951075-B2 | Pteridines useful as HCV inhibitors and methods for the preparation thereof | JANSSEN SCIENCES IRELAND UC (IE) | 2018-04-24 | — | — | US | disclosed |
| US-9951075-B2 | Pteridines useful as HCV inhibitors and methods for the preparation thereof | JANSSEN SCIENCES IRELAND UC (IE) | 2018-04-24 | — | — | US | disclosed |
| US-20170275288-A1 | PTERIDINES USEFUL AS HCV INHIBITORS AND METHODS FOR THE PREPARATION THEREOF | JANSSEN SCIENCES IRELAND UC (IE) | 2017-09-28 | — | — | US | disclosed |
| US-20170275288-A1 | PTERIDINES USEFUL AS HCV INHIBITORS AND METHODS FOR THE PREPARATION THEREOF | JANSSEN SCIENCES IRELAND UC (IE) | 2017-09-28 | — | — | US | disclosed |
| US-20170275288-A1 | PTERIDINES USEFUL AS HCV INHIBITORS AND METHODS FOR THE PREPARATION THEREOF | JANSSEN SCIENCES IRELAND UC (IE) | 2017-09-28 | — | — | US | disclosed |
| US-9708328-B2 | Pteridines useful as HCV inhibitors and methods for the preparation thereof | JANSSEN SCIENCES IRELAND UC (IE) | 2017-07-18 | — | — | US | disclosed |
| US-9708328-B2 | Pteridines useful as HCV inhibitors and methods for the preparation thereof | JANSSEN SCIENCES IRELAND UC (IE) | 2017-07-18 | — | — | US | disclosed |
| US-9708328-B2 | Pteridines useful as HCV inhibitors and methods for the preparation thereof | JANSSEN SCIENCES IRELAND UC (IE) | 2017-07-18 | — | — | US | disclosed |
| US-20160159803-A1 | Pteridines Useful As HCV Inhibitors And Methods For The Preparation Thereof | Janssen Sciences Ireland Unlimited Company (IE) | 2016-06-09 | — | — | US | disclosed |
| US-20160159803-A1 | Pteridines Useful As HCV Inhibitors And Methods For The Preparation Thereof | Janssen Sciences Ireland Unlimited Company (IE) | 2016-06-09 | — | — | US | disclosed |
| US-9290502-B2 | Pteridines useful as HCV inhibitors and methods for the preparation thereof | JANSSEN SCIENCES IRELAND UC (IE) | 2016-03-22 | — | — | US | disclosed |
| US-9290502-B2 | Pteridines useful as HCV inhibitors and methods for the preparation thereof | JANSSEN SCIENCES IRELAND UC (IE) | 2016-03-22 | — | — | US | disclosed |
| EP-1881834-B1 | PTERIDINES USEFUL AS HCV INHIBITORS AND METHODS FOR THE PREPARATION THEREOF | JANSSEN R & D IRELAND (IE) | 2012-04-25 | — | — | EP | disclosed |
| EP-1881834-B1 | PTERIDINES USEFUL AS HCV INHIBITORS AND METHODS FOR THE PREPARATION THEREOF | JANSSEN R & D IRELAND (IE) | 2012-04-25 | — | — | EP | disclosed |
| US-20090156595-A1 | Pteridines useful as HCV inhibitors and methods for the preparation thereof | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2009-06-18 | — | — | US | disclosed |
| US-20090156595-A1 | Pteridines useful as HCV inhibitors and methods for the preparation thereof | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2009-06-18 | — | — | US | disclosed |
| US-20090156595-A1 | Pteridines useful as HCV inhibitors and methods for the preparation thereof | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2009-06-18 | — | — | US | disclosed |
| EP-1881834-A1 | PTERIDINES USEFUL AS HCV INHIBITORS AND METHODS FOR THE PREPARATION THEREOF | Tibotec Pharmaceuticals Ltd. (IE) | 2008-01-30 | — | — | EP | disclosed |
| WO-2006120251-A1 | PTERIDINES USEFUL AS HCV INHIBITORS AND METHODS FOR THE PREPARATION THEREOF | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2006-11-16 | — | — | WO | disclosed |
| WO-2006120251-A1 | PTERIDINES USEFUL AS HCV INHIBITORS AND METHODS FOR THE PREPARATION THEREOF | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2006-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159803-A1 | Pteridines Useful As HCV Inhibitors And Methods For The Preparation Thereof | HCCS, HAVCR2, MAVS | AMY1A 4559/4885PTGES 749/4885CSNK2A2 3712/4885 |
| US-20170275288-A1 | PTERIDINES USEFUL AS HCV INHIBITORS AND METHODS FOR THE PREPARATION THEREOF | HCCS, HAVCR2, MAVS | AMY1A 4559/4885PTGES 749/4885CSNK2A2 3712/4885 |
| US-20090156595-A1 | Pteridines useful as HCV inhibitors and methods for the preparation thereof | HCCS, HAVCR2, MAVS | AMY1A 4559/4885PTGES 749/4885CSNK2A2 3712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.